Carolina Rodriguez, 26, receives a Johnson & Johnson COVID-19 vaccine at Booker T. Washington High School in Houston on Mar. 29, 2021.
Go Nakamura—The New York Times/Redux

When it comes to vaccinating the world, the simpler the dosing regimen the better. That’s why public-health officials welcomed Johnson & Johnson–Janssen Pharmaceuticals’ one-dose COVID-19 vaccine. The shot is 66% efficacious overall in protecting people from COVID-19 disease, and even more so in preventing the worst outcomes. After concerns were raised over rare blood-clotting side effects, U.S. health officials paused use of the shot in early April but resumed vaccination—with the potential clotting risk listed among the side effects—after determining the benefits outweigh the risks.

More Must-Reads from TIME

Contact us at